Reteplase
- Generic Name
- Reteplase
- Brand Names
- Retavase, Rapilysin
- Drug Type
- Biotech
- CAS Number
- 133652-38-7
- Unique Ingredient Identifier
- DQA630RIE9
- Background
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
- Indication
For lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction.
- Associated Conditions
- Acute Myocardial Infarction (AMI), Cardiovascular Mortality, Congestive Heart Failure (CHF)
Endovascular Stroke Treatment And Reteplase Protocol
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Zeenat Qureshi Stroke Institute
- Registration Number
- NCT05900674
A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1412
- Registration Number
- NCT05295173
- Locations
- 🇨🇳
Hengshui People's Hospital, Hengshui, Hebei, China
🇨🇳Anyang People's Hospital, Anyang, Henan, China
🇨🇳The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China
Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention
- Conditions
- Acute ST-segment Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Ge Junbo
- Target Recruit Count
- 36
- Registration Number
- NCT04571580
- Locations
- 🇨🇳
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)
- Conditions
- Acute Pulmonary Embolism
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT04110275
A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT04028518
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction
- Conditions
- Acute Myocardial Infarction
- Interventions
- Procedure: primary PCI
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2008-12-10
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Target Recruit Count
- 205
- Registration Number
- NCT00806403
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden
🇸🇪Orebro University Hospital, Orebro, Sweden
🇸🇪Norra Alvsborgs lans Hospital, Trollhattan, Sweden
Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
- Conditions
- Heart DiseaseMyocardial InfarctionAcute Myocardial Infarction
- Interventions
- Procedure: Primary Percutaneous Coronary Intervention (PCI)Procedure: Urgent Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-09-06
- Target Recruit Count
- 390
- Registration Number
- NCT00178620
- Locations
- 🇺🇸
Memorial Hermann Hospital / The University of Texas HSC, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.